Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
valaciclovir granules · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| valaciclovir HCl granules | DRUG | - |
Inclusion criteria: * Subjects aged 1 year to less than 12 years with a clinical diagnosis of chickenpox within 48 hours of the onset of the rash. Exclusion criteria: * History of hypersensitivity reactions. * Impaired hepatic or renal function. * Gastrointestinal dysfunction. * Serious underlyin...
Valaciclovir granules are used for the treatment of varicella, commonly known as chickenpox. The drug is being developed as a small molecule therapy for this infectious disease. It is currently in Phase 3 clinical development, though the specific trial for this indication has been completed.
Valaciclovir granules are being developed by GSK plc, which trades under the ticker GSK. The company is advancing this small molecule therapy for the treatment of varicella, or chickenpox. The drug is currently in Phase 3 clinical development.
Valaciclovir granules are in Phase 3 clinical development for the treatment of varicella. The Phase 3 trial, identified as NCT00169416, has been completed. The drug is investigational and has not been approved for use, as it remains in clinical development.
Valaciclovir granules have been studied in one clinical trial, identified as NCT00169416, titled "Evaluation Of Valaciclovir In Patients With Chickenpox." This Phase 3 trial enrolled 43 participants with varicella and has been completed. The trial was uncontrolled and did not use randomization or blinding.
Valaciclovir granules are not FDA approved. The drug is investigational and has completed a Phase 3 clinical trial for varicella, but approval status has not been established. It remains in clinical development, and no regulatory approval has been granted based on available information.